Plain-English translation of NCT05592678 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This research study is testing donepezil, a medication that is already used to treat Alzheimer's disease and mild memory problems, to see how well it works in different people. The research team will first predict which participants are most likely to benefit from the medication based on information you provide. Then, during the study, researchers will carefully track changes in your thinking and memory to see if the medication helps, and whether certain biological markers in your blood might explain why it works better for some people than others.
One size does not fit all in treating memory loss—this medication helps some people much more than others, and doctors don't yet have a reliable way to predict who will benefit. This study aims to develop better methods to identify which patients are most likely to respond to treatment, so that in the future, people with memory problems can get the right medication for their specific situation.
You likely qualify if…
You likely don't qualify if…
The study begins with a phone call to assess whether you might benefit from the medication based on your caregiving partner's observations of your memory. If you qualify, you will be assigned to either a predicted responder or non-responder group based on this assessment. You will then take donepezil (prescribed as you normally would by your doctor) while the research team tracks your thinking and memory through visits and tests, including blood work to measure biological markers. The study is designed as a double-blind study, meaning neither you nor some of the research team will know which group you're in until the study is complete.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
United States